JMP Securities Maintains Market Outperform on Crinetics Pharmaceuticals, Raises Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has maintained a Market Outperform rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and increased the price target from $60 to $80.
March 20, 2024 | 1:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has raised the price target for Crinetics Pharmaceuticals from $60 to $80 while maintaining a Market Outperform rating.
The increase in price target by a reputable analyst firm like JMP Securities typically signals a strong bullish outlook on the stock, suggesting potential upside. This is based on the firm's analysis and confidence in the company's future performance. Such a significant increase in the price target can lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100